Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.32)
# 1,016
Out of 4,966 analysts
207
Total ratings
49.59%
Success rate
2.23%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Overweight | $975 → $825 | $732.58 | +12.62% | 13 | Aug 13, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $391.02 | +24.03% | 4 | Aug 5, 2025 | |
| AMGN Amgen | Reiterates: Neutral | $305 | $287.71 | +6.01% | 17 | Jun 24, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $47.18 | +16.57% | 16 | Apr 23, 2025 | |
| REGN Regeneron Pharmaceuticals | Assumes: Overweight | $695 | $580.70 | +19.68% | 20 | Apr 22, 2025 | |
| PFE Pfizer | Initiates: Neutral | $24 | $24.76 | -3.07% | 15 | Apr 22, 2025 | |
| PCVX Vaxcyte | Initiates: Overweight | n/a | $30.79 | - | 1 | Apr 22, 2025 | |
| MRK Merck & Co. | Initiates: Neutral | $85 | $84.12 | +1.05% | 11 | Apr 22, 2025 | |
| GILD Gilead Sciences | Assumes: Overweight | $125 | $112.97 | +10.65% | 15 | Apr 22, 2025 | |
| ABBV AbbVie | Initiates: Overweight | $210 | $210.40 | -0.19% | 15 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $139.60 | +18.19% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $17.50 | +14.29% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $132.22 | +36.14% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $100 | $76.58 | +30.58% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $3 | $1.97 | +52.28% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $1.12 | +167.86% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.40 | +542.86% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $35.33 | +168.89% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $15.37 | +30.12% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $69.39 | +5.20% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $2.35 | +410.64% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $2.47 | -39.27% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.49 | +356.67% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $227.15 | +67.29% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $84.61 | -3.08% | 5 | Jan 16, 2019 |
Eli Lilly and Company
Aug 13, 2025
Maintains: Overweight
Price Target: $975 → $825
Current: $732.58
Upside: +12.62%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $391.02
Upside: +24.03%
Amgen
Jun 24, 2025
Reiterates: Neutral
Price Target: $305
Current: $287.71
Upside: +6.01%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $47.18
Upside: +16.57%
Regeneron Pharmaceuticals
Apr 22, 2025
Assumes: Overweight
Price Target: $695
Current: $580.70
Upside: +19.68%
Pfizer
Apr 22, 2025
Initiates: Neutral
Price Target: $24
Current: $24.76
Upside: -3.07%
Vaxcyte
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $30.79
Upside: -
Merck & Co.
Apr 22, 2025
Initiates: Neutral
Price Target: $85
Current: $84.12
Upside: +1.05%
Gilead Sciences
Apr 22, 2025
Assumes: Overweight
Price Target: $125
Current: $112.97
Upside: +10.65%
AbbVie
Apr 22, 2025
Initiates: Overweight
Price Target: $210
Current: $210.40
Upside: -0.19%
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $139.60
Upside: +18.19%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $17.50
Upside: +14.29%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $132.22
Upside: +36.14%
Aug 29, 2024
Initiates: Overweight
Price Target: $100
Current: $76.58
Upside: +30.58%
Aug 14, 2024
Maintains: Overweight
Price Target: $10 → $3
Current: $1.97
Upside: +52.28%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $1.12
Upside: +167.86%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.40
Upside: +542.86%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $35.33
Upside: +168.89%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $15.37
Upside: +30.12%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $69.39
Upside: +5.20%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $2.35
Upside: +410.64%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $2.47
Upside: -39.27%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.49
Upside: +356.67%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $227.15
Upside: +67.29%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $84.61
Upside: -3.08%